Göran Ando föreslagen som ny styrelseordförande i Nanexa AB (publ)
Uppsala April 22, 2020
Göran Ando proposed as new Chairman of the Board of Nanexa AB (publ)
A group of shareholders in Nanexa AB, who together represent at least 11 percent of the shares and votes in the company, have informed the Board and the CEO that they, at the Annual General Meeting on June 2, 2020, will propose Göran Ando as the new Chairman of the Board. Göran Ando has accepted the offer, provided that the AGM elects him.
Dr. Ando began his career in the pharmaceutical industry in 1978 as medical director of Pfizer AB, continued as director of clinical research with Pfizer International in the United States. Dr. Ando then became ‘VP, Medical and Scientific Affairs’ at Bristol-Myers and returned to Sweden as chair of the Astra Research Center. Between 1989 and 1995, he held a number of senior positions at Glaxo, including research and development manager for Glaxo Group Research.
Dr. Ando joined Pharmacia AB in 1995 as Executive Vice President and Deputy CEO and moved to the USA in 1997 to lead research and development with additional responsibility for manufacturing, information technology, business development and mergers and acquisitions. During his eight-year tenure as Head of Research and Development at Pharmacia / Pharmacia & Upjohn, 17 new drugs were approved by the U.S. Food & Drug Administration (FDA) prior to Pfizer’s acquisition of Pharmacia. Dr. Ando was then named CEO of Celltech Group PLC in the UK, one of the most successful European biotech companies, until it was acquired by UCB Pharma in 2005.
Göran Ando was chairman of the board of Novo Nordisk A / S and resigned from that position in 2018.
Dr. Ando received his bachelor’s degree from Uppsala University in Sweden and his Doctorate in Medicine from Linköping University in Sweden.
We in the group of shareholders are extremely pleased that Göran Ando, with his very solid expertise and broad experience, has accepted the important position as Chairman of the Board of Nanexa. We are confident that he will be able to add a great deal to the company, says Anders Johansson, co-founder and part of the shareholder group.
Nanexa’s CEO David Westberg comments: It will be extremely interesting to work with Göran Ando and it can be very good for the development of the company, not least in contacts with global pharmaceutical companies.
For further information:
Nanexa AB (publ)
David Westberg, VD
Phone: +46 709 42 83 03
E mail: email@example.com
About Nanexa AB (publ)
Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.